uniQure N.V. $QURE Stock Position Lowered by Monaco Asset Management SAM

Monaco Asset Management SAM decreased its position in uniQure N.V. (NASDAQ:QURE) by 43.0% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 39,913 shares of the biotechnology company’s stock after selling 30,087 shares during the period. Monaco Asset Management SAM’s holdings in uniQure were worth $2,330,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of QURE. Woodline Partners LP increased its holdings in shares of uniQure by 25.0% in the 1st quarter. Woodline Partners LP now owns 175,806 shares of the biotechnology company’s stock valued at $1,864,000 after purchasing an additional 35,175 shares during the period. Y Intercept Hong Kong Ltd purchased a new stake in uniQure in the 2nd quarter worth approximately $872,000. Teacher Retirement System of Texas acquired a new stake in shares of uniQure during the 2nd quarter valued at $151,000. Jennison Associates LLC acquired a new stake in shares of uniQure during the 2nd quarter valued at $1,952,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in shares of uniQure during the 2nd quarter valued at $215,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

uniQure News Roundup

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Technical strength signal — coverage notes uniQure met an 80-plus relative strength benchmark, which can attract momentum investors and offset some selling pressure. Read More.
• Neutral Sentiment: Near-term catalyst — uniQure is scheduled to release earnings this week; results and guidance could swing sentiment and either aggravate or alleviate current selling related to the lawsuits. Read More.
• Negative Sentiment: Class-action filing by Kessler Topaz alleges securities fraud covering the Sept. 24–Oct. 31, 2025 period and sets an April 13, 2026 lead‑plaintiff deadline — this is a direct legal headline likely to weigh on the stock. Read More.
• Negative Sentiment: Multiple law firms (Schall, Faruqi & Faruqi, Pomerantz, Rosen, DJS, Bronstein Gewirtz & Grossman, Bernstein Liebhard, Portnoy, ClaimsFiler and others) have issued investor alerts and filings reminding shareholders of deadlines — the volume of notices magnifies perceived risk and creates sustained news flow and potential selling pressure. Read More.
• Negative Sentiment: Investor outreach emphasizes recoveries for specific loss thresholds and encourages lead‑plaintiff motions — if a strong lead plaintiff emerges, the case could proceed aggressively, increasing potential cost and uncertainty for the company. Read More.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. Royal Bank Of Canada cut their price objective on uniQure from $65.00 to $45.00 and set an “outperform” rating for the company in a report on Monday, November 3rd. Wall Street Zen lowered uniQure from a “hold” rating to a “sell” rating in a research report on Sunday, January 11th. William Blair reaffirmed a “market perform” rating on shares of uniQure in a research note on Tuesday, November 11th. Mizuho reduced their price target on uniQure from $60.00 to $33.00 and set an “outperform” rating for the company in a report on Monday, December 8th. Finally, Leerink Partners dropped their price objective on uniQure from $68.00 to $60.00 and set an “outperform” rating on the stock in a report on Monday, November 10th. Ten research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, uniQure currently has an average rating of “Moderate Buy” and an average price target of $58.33.

uniQure Price Performance

Shares of uniQure stock opened at $23.43 on Friday. The firm has a fifty day simple moving average of $23.60 and a 200-day simple moving average of $29.33. The company has a current ratio of 7.12, a quick ratio of 7.12 and a debt-to-equity ratio of 0.23. uniQure N.V. has a 1-year low of $7.76 and a 1-year high of $71.50. The stock has a market capitalization of $1.46 billion, a price-to-earnings ratio of -5.34 and a beta of 0.66.

Insider Buying and Selling at uniQure

In other uniQure news, Director Robert Gut sold 25,613 shares of the company’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $24.62, for a total transaction of $630,592.06. Following the completion of the sale, the director directly owned 32,342 shares in the company, valued at $796,260.04. This represents a 44.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jack Kaye sold 6,390 shares of the firm’s stock in a transaction that occurred on Friday, January 9th. The shares were sold at an average price of $27.28, for a total value of $174,319.20. Following the completion of the sale, the director directly owned 20,439 shares in the company, valued at $557,575.92. This trade represents a 23.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 4.79% of the company’s stock.

uniQure Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.